quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:21·3d
SECFiling
ENDRA Life Sciences Inc. logo

ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

NDRA· ENDRA Life Sciences Inc.
Health Care
Original source

Companies

  • NDRA
    ENDRA Life Sciences Inc.
    Health Care

Related

  • SEC23d
    SEC Form 10-K filed by ENDRA Life Sciences Inc.
  • SEC23d
    ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR23d
    ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • SEC29d
    ENDRA Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR30d
    ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
  • INSIDER50d
    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)
  • INSIDER50d
    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)
  • PR56d
    ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022